The company said it is developing a new genomic test to predict therapeutic response in patients with inflammatory skin conditions.
The company recently acquired PFS Genomics, which has developed a test to determine the necessity of radiotherapy for breast cancer patients.
As diagnostics firms develop a new wave of COVID-19 tests using next-gen sequencing, TGen researchers are also adding CRISPR-based sample prep to their kit.
The 20-year study showed the test provided an accurate assessment of the risk of long-term metastases and mortality for patients with localized prostate cancer.
The company is also continuing to expand its digital technology offering to help clinicians track their patients' health more easily.
The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.
The researchers hope that donor-derived cell-free DNA testing to monitor rejection can help relieve racial disparities in heart transplant outcomes.
The pace of development for CRISPR-based infectious disease assays increased as the pandemic progressed, more funding became available, and collaboration accelerated.
The two new tests, which have the capability to quantify a patient's viral load, have been designed without external RNA extraction or amplification steps.
The company said the improvements it has made to its business during the pandemic will translate to significant increases in growth once it ends.